LT2928495T - Kompozicijos, apimančios anti-cd38 antikūnus ir lenalidomidą - Google Patents
Kompozicijos, apimančios anti-cd38 antikūnus ir lenalidomidąInfo
- Publication number
- LT2928495T LT2928495T LTEP13861470.6T LT13861470T LT2928495T LT 2928495 T LT2928495 T LT 2928495T LT 13861470 T LT13861470 T LT 13861470T LT 2928495 T LT2928495 T LT 2928495T
- Authority
- LT
- Lithuania
- Prior art keywords
- lenalidomide
- antibodies
- compositions including
- including anti
- compositions
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
- A61K31/37—Coumarins, e.g. psoralen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
- A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
- A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
- A61K31/727—Heparin; Heparan
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Dermatology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Neurosurgery (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261734524P | 2012-12-07 | 2012-12-07 | |
| US201361769247P | 2013-02-26 | 2013-02-26 | |
| US201361808372P | 2013-04-04 | 2013-04-04 | |
| PCT/US2013/073540 WO2014089416A1 (en) | 2012-12-07 | 2013-12-06 | Compositions comprising anti-cd38 antibodies and lenalidomide |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| LT2928495T true LT2928495T (lt) | 2019-07-10 |
Family
ID=50884019
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| LTEP13861470.6T LT2928495T (lt) | 2012-12-07 | 2013-12-06 | Kompozicijos, apimančios anti-cd38 antikūnus ir lenalidomidą |
| LTPA2020537C LTC2928495I2 (lt) | 2012-12-07 | 2020-11-30 | Kompozicijos, apimančios anti-cd38 antikūnus ir lenalidomidą |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| LTPA2020537C LTC2928495I2 (lt) | 2012-12-07 | 2020-11-30 | Kompozicijos, apimančios anti-cd38 antikūnus ir lenalidomidą |
Country Status (31)
| Country | Link |
|---|---|
| EP (2) | EP3597191A1 (enExample) |
| JP (2) | JP6499971B2 (enExample) |
| KR (2) | KR20200143503A (enExample) |
| CN (1) | CN105263520B (enExample) |
| AR (1) | AR093844A1 (enExample) |
| AU (2) | AU2013355064B2 (enExample) |
| BR (1) | BR112015012987A2 (enExample) |
| CA (1) | CA2893946A1 (enExample) |
| CL (2) | CL2015001558A1 (enExample) |
| CY (2) | CY1122478T1 (enExample) |
| DK (1) | DK2928495T3 (enExample) |
| ES (1) | ES2731548T3 (enExample) |
| HR (1) | HRP20191034T1 (enExample) |
| HU (3) | HUE044142T2 (enExample) |
| IL (2) | IL239234B (enExample) |
| LT (2) | LT2928495T (enExample) |
| LU (1) | LUC00187I2 (enExample) |
| MX (2) | MX366296B (enExample) |
| MY (1) | MY191601A (enExample) |
| NL (1) | NL301079I2 (enExample) |
| NZ (1) | NZ709215A (enExample) |
| PH (1) | PH12015501263A1 (enExample) |
| PL (1) | PL2928495T3 (enExample) |
| PT (1) | PT2928495T (enExample) |
| RS (1) | RS58829B1 (enExample) |
| RU (1) | RU2698911C2 (enExample) |
| SG (3) | SG10201913783PA (enExample) |
| SI (1) | SI2928495T1 (enExample) |
| TW (2) | TW201919699A (enExample) |
| UA (1) | UA118255C2 (enExample) |
| WO (1) | WO2014089416A1 (enExample) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA112170C2 (uk) | 2010-12-10 | 2016-08-10 | Санофі | Протипухлинна комбінація, що містить антитіло, яке специфічно розпізнає cd38, і бортезоміб |
| JOP20210044A1 (ar) | 2010-12-30 | 2017-06-16 | Takeda Pharmaceuticals Co | الأجسام المضادة لـ cd38 |
| US10342869B2 (en) | 2012-12-07 | 2019-07-09 | The Regents Of The University Of California | Compositions comprising anti-CD38 antibodies and lenalidomide |
| US9603927B2 (en) | 2014-02-28 | 2017-03-28 | Janssen Biotech, Inc. | Combination therapies with anti-CD38 antibodies |
| US9732154B2 (en) | 2014-02-28 | 2017-08-15 | Janssen Biotech, Inc. | Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia |
| WO2015195555A1 (en) * | 2014-06-16 | 2015-12-23 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Blocking cd38 using anti-cd38 antibody conjugated to protein g to protect nk cells |
| US10617757B2 (en) | 2014-08-08 | 2020-04-14 | The Regents Of The University Of California | Methods for treating multiple myeloma |
| PE20171094A1 (es) | 2014-12-04 | 2017-08-07 | Janssen Biotech Inc | Anticuerpos anti-cd38 para el tratamiento de la leucemia linfoblastica aguda |
| CR20170526A (es) | 2015-05-20 | 2018-04-03 | Janssen Biotech Inc | ANTICUERPOS ANTI-CD38 PARA EL TRATAMIENTO DE AMILOIDOSIS DE CADENA LIGERA y OTRAS ENFERMEDADES MALIGNAS HEMATOLÓGICAS POSITIVAS PARA CD38 |
| CN107708734B (zh) | 2015-06-22 | 2022-01-11 | 詹森生物科技公司 | 用抗cd38抗体和生存素抑制剂联合治疗血红素恶性肿瘤 |
| US20170044265A1 (en) | 2015-06-24 | 2017-02-16 | Janssen Biotech, Inc. | Immune Modulation and Treatment of Solid Tumors with Antibodies that Specifically Bind CD38 |
| US10781261B2 (en) | 2015-11-03 | 2020-09-22 | Janssen Biotech, Inc. | Subcutaneous formulations of anti-CD38 antibodies and their uses |
| JP7027321B2 (ja) | 2015-11-03 | 2022-03-01 | ヤンセン バイオテツク，インコーポレーテツド | 抗ｃｄ３８抗体の皮下製剤及びその使用 |
| WO2018002181A1 (en) | 2016-06-28 | 2018-01-04 | Umc Utrecht Holding B.V. | TREATMENT OF IgE-MEDIATED DISEASES WITH ANTIBODIES THAT SPECIFICALLY BIND CD38 |
| MA45674A (fr) | 2016-07-15 | 2019-05-22 | Takeda Pharmaceuticals Co | Méthodes et matériaux permettant d'évaluer une réponse à des traitements de déplétion de plasmoblastes et de plasmocytes |
| US11618787B2 (en) | 2017-10-31 | 2023-04-04 | Janssen Biotech, Inc. | Methods of treating high risk multiple myeloma |
| MX2020007429A (es) | 2018-01-12 | 2020-10-15 | Takeda Pharmaceuticals Co | Dosificacion subcutanea de anticuerpos anti grupo de diferenciacion 38 (cd38). |
| KR102286500B1 (ko) * | 2018-04-13 | 2021-08-05 | 주식회사 삼양홀딩스 | 레날리도마이드를 포함하는 경구용 고형제제의 제조방법 |
| JP7581052B2 (ja) * | 2018-04-13 | 2024-11-12 | サムヤン ホールディングス コーポレイション | レナリドミドの経口用コーティング錠剤組成物 |
| WO2019199135A1 (ko) * | 2018-04-13 | 2019-10-17 | 주식회사 삼양바이오팜 | 레날리도마이드를 포함하는 경구용 고형제제의 제조방법 |
| KR102286497B1 (ko) * | 2018-04-13 | 2021-08-05 | 주식회사 삼양홀딩스 | 다양한 용량의 레날리도마이드의 경구용 정제 조성물 |
| WO2019199134A1 (ko) * | 2018-04-13 | 2019-10-17 | 주식회사 삼양바이오팜 | 레날리도마이드를 포함하는 약제학적 조성물 |
| WO2019220368A1 (en) | 2018-05-16 | 2019-11-21 | Janssen Biotech, Inc. | Bcma/cd3 and gprdc5d/cd3 bispecific antibodies for use in cancer therapy |
| CA3114401A1 (en) * | 2018-10-01 | 2020-04-09 | Celgene Corporation | Combination therapy for the treatment of cancer |
| TWI924633B (zh) * | 2019-03-15 | 2026-05-11 | 德商莫菲西斯公司 | 用於治療自體抗體介導的自體免疫疾病的抗-cd38 抗體及其醫藥組成物 |
| US11655302B2 (en) | 2019-06-10 | 2023-05-23 | Sanofi | Anti-CD38 antibodies and formulations |
| WO2020250033A1 (en) * | 2019-06-10 | 2020-12-17 | Takeda Pharmaceutical Company Limited | Combination therapies using cd-38 antibodies |
| WO2021084062A1 (en) * | 2019-10-31 | 2021-05-06 | Morphosys Ag | Anti-cd19 therapy in combination with lenalidomide for the treatment of leukemia or lymphoma |
| AU2020397170A1 (en) | 2019-12-05 | 2022-07-21 | Sanofi-Aventis U.S. Llc | Formulations of anti-CD38 antibodies for subcutaneous administration |
| US20250277051A1 (en) * | 2021-08-02 | 2025-09-04 | Hangzhou Unogen Biotech, Ltd | Anti-cd38 antibodies, anti-cd3 antibodies, and bispecific antibodies, and uses thereof |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4444887A (en) | 1979-12-10 | 1984-04-24 | Sloan-Kettering Institute | Process for making human antibody producing B-lymphocytes |
| US4716111A (en) | 1982-08-11 | 1987-12-29 | Trustees Of Boston University | Process for producing human antibodies |
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5807715A (en) | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
| EP1690935A3 (en) | 1990-01-12 | 2008-07-30 | Abgenix, Inc. | Generation of xenogeneic antibodies |
| US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| DE69233482T2 (de) | 1991-05-17 | 2006-01-12 | Merck & Co., Inc. | Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen |
| EP0590058B1 (en) | 1991-06-14 | 2003-11-26 | Genentech, Inc. | HUMANIZED Heregulin ANTIBODy |
| ES2136092T3 (es) | 1991-09-23 | 1999-11-16 | Medical Res Council | Procedimientos para la produccion de anticuerpos humanizados. |
| US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
| CA2219361C (en) | 1995-04-27 | 2012-02-28 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| WO1996034096A1 (en) | 1995-04-28 | 1996-10-31 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US5916771A (en) | 1996-10-11 | 1999-06-29 | Abgenix, Inc. | Production of a multimeric protein by cell fusion method |
| EP1972194A1 (en) | 1996-12-03 | 2008-09-24 | Amgen Fremont Inc. | Transgenic mammals having human ig loci including plural vh and vk regions and antibodies produced therefrom |
| JP3876002B2 (ja) | 1997-04-14 | 2007-01-31 | ミクロメート・アクチエンゲゼルシャフト | 抗ヒト抗原受容体を産生するための斬新な方法およびそれらの使用 |
| US6235883B1 (en) | 1997-05-05 | 2001-05-22 | Abgenix, Inc. | Human monoclonal antibodies to epidermal growth factor receptor |
| TWI397540B (zh) * | 2004-12-21 | 2013-06-01 | Nippon Kayaku Kk | 環氧樹脂，環氧樹脂組成物及其硬化物 |
| EP2551282A3 (en) * | 2005-03-23 | 2013-02-13 | Genmab A/S | Antibodies against CD38 for treatment of multiple myeloma |
| PL2081595T3 (pl) * | 2006-09-26 | 2019-11-29 | Genmab As | Anty-cd38 wraz z kortykosteroidami wraz ze środkiem chemioterapeutycznym niebędącym kortykosteroidem, do leczenia guzów nowotworowych |
| EP1914242A1 (en) * | 2006-10-19 | 2008-04-23 | Sanofi-Aventis | Novel anti-CD38 antibodies for the treatment of cancer |
| EP2191840A1 (en) * | 2008-11-28 | 2010-06-02 | Sanofi-Aventis | Antitumor combinations containing antibodies recognizing specifically CD38 and melphalan |
| EP2191843A1 (en) * | 2008-11-28 | 2010-06-02 | Sanofi-Aventis | Antitumor combinations containing antibodies recognizing specifically CD38 and cyclophosphamide |
| US8877899B2 (en) * | 2010-09-27 | 2014-11-04 | Morphosys Ag | Anti-CD38 antibody and lenalidomide or bortezomib for the treatment of multipe myeloma and NHL |
| JOP20210044A1 (ar) * | 2010-12-30 | 2017-06-16 | Takeda Pharmaceuticals Co | الأجسام المضادة لـ cd38 |
-
2013
- 2013-06-12 UA UAA201506686A patent/UA118255C2/uk unknown
- 2013-12-06 EP EP19164801.3A patent/EP3597191A1/en not_active Withdrawn
- 2013-12-06 SI SI201331472T patent/SI2928495T1/sl unknown
- 2013-12-06 ES ES13861470T patent/ES2731548T3/es active Active
- 2013-12-06 TW TW107134543A patent/TW201919699A/zh unknown
- 2013-12-06 LT LTEP13861470.6T patent/LT2928495T/lt unknown
- 2013-12-06 RU RU2015127089A patent/RU2698911C2/ru active
- 2013-12-06 SG SG10201913783PA patent/SG10201913783PA/en unknown
- 2013-12-06 SG SG11201504315WA patent/SG11201504315WA/en unknown
- 2013-12-06 CN CN201380063714.0A patent/CN105263520B/zh active Active
- 2013-12-06 EP EP13861470.6A patent/EP2928495B1/en active Active
- 2013-12-06 TW TW102145031A patent/TWI670062B/zh active
- 2013-12-06 HU HUE13861470A patent/HUE044142T2/hu unknown
- 2013-12-06 PL PL13861470T patent/PL2928495T3/pl unknown
- 2013-12-06 AR ARP130104546A patent/AR093844A1/es unknown
- 2013-12-06 DK DK13861470.6T patent/DK2928495T3/da active
- 2013-12-06 RS RS20190711A patent/RS58829B1/sr unknown
- 2013-12-06 NZ NZ709215A patent/NZ709215A/en unknown
- 2013-12-06 MY MYPI2015701779A patent/MY191601A/en unknown
- 2013-12-06 HR HRP20191034TT patent/HRP20191034T1/hr unknown
- 2013-12-06 SG SG10201704536PA patent/SG10201704536PA/en unknown
- 2013-12-06 WO PCT/US2013/073540 patent/WO2014089416A1/en not_active Ceased
- 2013-12-06 PT PT13861470T patent/PT2928495T/pt unknown
- 2013-12-06 MX MX2015007189A patent/MX366296B/es active IP Right Grant
- 2013-12-06 JP JP2015545868A patent/JP6499971B2/ja active Active
- 2013-12-06 KR KR1020207035944A patent/KR20200143503A/ko not_active Ceased
- 2013-12-06 CA CA2893946A patent/CA2893946A1/en not_active Abandoned
- 2013-12-06 KR KR1020157017942A patent/KR102193045B1/ko active Active
- 2013-12-06 AU AU2013355064A patent/AU2013355064B2/en active Active
- 2013-12-06 BR BR112015012987A patent/BR112015012987A2/pt not_active Application Discontinuation
-
2015
- 2015-06-03 PH PH12015501263A patent/PH12015501263A1/en unknown
- 2015-06-04 IL IL239234A patent/IL239234B/en active IP Right Grant
- 2015-06-05 MX MX2019008065A patent/MX2019008065A/es unknown
- 2015-06-05 CL CL2015001558A patent/CL2015001558A1/es unknown
-
2018
- 2018-08-01 AU AU2018211258A patent/AU2018211258A1/en not_active Abandoned
- 2018-11-20 CL CL2018003292A patent/CL2018003292A1/es unknown
-
2019
- 2019-01-11 JP JP2019003132A patent/JP2019070020A/ja active Pending
- 2019-06-26 CY CY20191100667T patent/CY1122478T1/el unknown
-
2020
- 2020-11-25 LU LU00187C patent/LUC00187I2/fr unknown
- 2020-11-27 CY CY2020040C patent/CY2020040I2/el unknown
- 2020-11-30 LT LTPA2020537C patent/LTC2928495I2/lt unknown
- 2020-11-30 NL NL301079C patent/NL301079I2/nl unknown
- 2020-11-30 HU HUS2000050C patent/HUS2000050I1/hu unknown
- 2020-11-30 HU HUS2000051C patent/HUS2000051I1/hu unknown
-
2021
- 2021-04-21 IL IL282542A patent/IL282542A/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| LTPA2020537I1 (lt) | Kompozicijos, apimančios anti-CD38 antikūnus ir lenalidomidą | |
| CY2024011I1 (el) | Αντισωματα anti-fcrn | |
| LT2970456T (lt) | Būdai ir kompozicijos, skirti mrnr koduojamų antikūnų pristatymui | |
| IL237625A0 (en) | Antibodies against m-cam, preparations containing them and their uses | |
| IL238192A0 (en) | Antibodies that recognize alpha-synuclei, preparations containing them and their uses | |
| DK2934584T3 (da) | Anti-gdf15-antistoffer | |
| HRP20181646T1 (hr) | Konjugati pirolobenzodiazepin - anti-psma protutijela | |
| SG11201509361TA (en) | Novel antibodies | |
| IL235004A0 (en) | Antibodies against fgfr2, preparations containing them and their uses | |
| BR112013017009A2 (pt) | anticorpos anti-cd38 | |
| HRP20181874T1 (hr) | Anti-cxcr3 protutijela | |
| PT2968555T (pt) | Composições compreendendo anticorpos anti-cd38 e carfilzomib | |
| HUE037613T2 (hu) | Anti-TLR4 antitestek és azok felhasználása | |
| DK2855530T3 (da) | Anti-transglutaminase 2-antistoffer | |
| DK2828292T3 (da) | Jcv-neutraliserende antistoffer | |
| DK2935330T3 (da) | Anti-notch3-antistoffer | |
| GB201312226D0 (en) | Improved antibodies | |
| EP2900693A4 (en) | ADCC-mediating antibodies, combinations and uses thereof | |
| LT2956129T (lt) | Farmacinės kompozicijos, turinčios deksketoprofeną ir tramadolį | |
| GB201209584D0 (en) | Modified antibodies |